2026-06-14T03:30:15Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/201492024-11-28T17:36:05Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16961col_20.500.12105_16967col_20.500.12105_16972
Repisalud
author
Diaz-Beya, Marina
author
Brunet, S
author
Nomdedeu, J
author
Cordeiro, Anna
author
Tormo, M
author
Escoda, Lourdes
author
Ribera, J. M
author
Arnan, M
author
Heras, Inmaculada
author
Gallardo, David
author
Bargay Lleonart, Joan
author
Queipo de Llano, Maria Paz
author
Salamero, O
author
Marti, J. M
author
Sampol Mayol, Antonia
author
Pedro, C
author
Hoyos, M
author
Pratcorona, M
author
Castellano, JJ
author
Nomdedeu, M
author
Risueno, RM
author
Sierra, J
author
Monzo, M
author
Navarro, A
author
Esteve, Jordi
2024-07-04T12:56:29Z
2024-07-04T12:56:29Z
2015-10
Diaz-Beya M, Brunet S, Nomdedeu J, Cordeiro A, Tormo M, Escoda L, et al. The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia. Blood Cancer J. 2015 Oct;5:e352.
10.1038/bcj.2015.76
2044-5385
Blood Cancer Journal
http://hdl.handle.net/20.500.13003/10668
26430723
L606212831
2-s2.0-84943169416
http://hdl.handle.net/20.500.12105/20149
368920300002
Acute myeloid leukemia (AML) is a heterogeneous disease whose prognosis is mainly related to the biological risk conferred by cytogenetics and molecular profiling. In elderly patients (>= 60 years) with normal karyotype AML miR-3151 have been identified as a prognostic factor. However, miR-3151 prognostic value has not been examined in younger AML patients. In the present work, we have studied miR-3151 alone and in combination with BAALC, its host gene, in a cohort of 181 younger intermediate-risk AML (IR-AML) patients. Patients with higher expression of miR-3151 had shorter overall survival (P = 0.0025), shorter leukemia-free survival (P = 0.026) and higher cumulative incidence of relapse (P = 0.082). Moreover, in the multivariate analysis miR-3151 emerged as independent prognostic marker in both the overall series and within the unfavorable molecular prognostic category. Interestingly, the combined determination of both miR-3151 and BAALC improved this prognostic stratification, with patients with low levels of both parameters showing a better outcome compared with those patients harboring increased levels of one or both markers (P = 0.003). In addition, we studied the microRNA expression profile associated with miR-3151 identifying a six-microRNA signature. In conclusion, the analysis of miR-3151 and BAALC expression may well contribute to an improved prognostic stratification of younger patients with IR-AML.
eng
The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia
research article